Literature DB >> 26361284

Comparison of the Dermatology Life Quality Index and the Children's Dermatology Life Quality Index in assessment of quality of life in patients with psoriasis aged 16-17 years.

M J van Geel1, M Maatkamp1, A M Oostveen1, E M G J de Jong1, A Y Finlay2, P C M van de Kerkhof1, M M B Seyger1.   

Abstract

BACKGROUND: Dermatology Life Quality Index (DLQI) and Children's Dermatology Life Quality Index (CDLQI) are widely used to assess quality of life (QoL) in adults (≥ 16 years) and children (4-16 years) with psoriasis. In the age group 16-17 years, it is not known whether DLQI and CDLQI reflect QoL impairment in the same way.
OBJECTIVES: To compare DLQI and CDLQI scores in patients with psoriasis aged 16-17 years.
METHODS: Patients with psoriasis aged 16-17 years were asked to complete both the DLQI and CDLQI.
RESULTS: Fifty-six patients were included. There was a high correlation between DLQI and CDLQI scores (r = 0·90, P < 0·001). The mean DLQI score (5·41 ± 5·20) was lower than the mean CDLQI (6·61 ± 5·74) (P < 0·001). The major part of this difference (∆0·61) was caused by the low score regarding sexual difficulties in the DLQI (0·11 ± 0·49) and the high score concerning sleep in the CDLQI (0·71 ± 0·93). In addition, the question related to sports scored 0·34 in the DLQI but 0·86 in the CDLQI (∆0·52). The question related to work/study in the DLQI scored lower than the question on school/holiday in the CDLQI (∆0·41).
CONCLUSIONS: In patients with psoriasis aged 16-17 years, DLQI and CDLQI scores closely correlate, but the mean DLQI score was lower than the mean CDLQI score. This was caused primarily by differences in the answers to questions regarding sexual difficulties and sleep. As the QoL impacts experienced by people aged 16-17 may differ from those experienced by children or adults, QoL measures designed for use in this age range may have advantages over both child- and adult-specific measures.
© 2015 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26361284     DOI: 10.1111/bjd.14163

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  9 in total

1.  Higher rates of skin clearance and efficacy in challenging body areas are associated with better health-related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis.

Authors:  Adelaide A Hebert; Margaret A Bobonich; Claudia Rodriguez Capriles; Gaia Gallo; Lingnan Li; Najwa Somani; Terri Ridenour; Yan Wang; Emily Edson-Heredia; Emily M Becker
Journal:  Pediatr Dermatol       Date:  2021-12-20       Impact factor: 1.997

Review 2.  Sleep Disturbances and Atopic Dermatitis: Relationships, Methods for Assessment, and Therapies.

Authors:  Fatima Bawany; Carrie A Northcott; Lisa A Beck; Wilfred R Pigeon
Journal:  J Allergy Clin Immunol Pract       Date:  2020-12-13

3.  Development and preliminary validation of the Adolescent Psoriasis Quality of Life instrument: a disease-specific measure of quality of life in adolescents with psoriasis.

Authors:  H Randa; L R Khoury; T K Grønborg; J J Lomholt; L Skov; R Zachariae
Journal:  Br J Dermatol       Date:  2020-01-29       Impact factor: 9.302

4.  Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).

Authors:  A S Paller; M M B Seyger; G Alejandro Magariños; J Bagel; A Pinter; J Cather; S Keller; C Rodriguez Capriles; R Gontijo Lima; G Gallo; C A Little; E Edson-Heredia; L Li; W Xu; K Papp
Journal:  Br J Dermatol       Date:  2020-06-15       Impact factor: 9.302

Review 5.  Mutual Influence of Psoriasis and Sport.

Authors:  Paolo Custurone; Laura Macca; Lucrezia Bertino; Debora Di Mauro; Fabio Trimarchi; Mario Vaccaro; Francesco Borgia
Journal:  Medicina (Kaunas)       Date:  2021-02-10       Impact factor: 2.430

Review 6.  Optimal Management of Plaque Psoriasis in Adolescents: Current Perspectives.

Authors:  Emmanuel Mahé
Journal:  Psoriasis (Auckl)       Date:  2020-11-27

7.  Unsettling experiences: A qualitative inquiry into young peoples' narratives of diagnosis for common skin conditions in the United Kingdom.

Authors:  Abigail McNiven; Sara Ryan
Journal:  Front Psychol       Date:  2022-09-15

8.  High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents.

Authors:  S Ständer; N Bhatia; M J Gooderham; J I Silverberg; J P Thyssen; P Biswas; M DiBonaventura; W Romero; S A Farooqui
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-05-06       Impact factor: 9.228

9.  Impact of Palmoplantar Dermatoses on Quality of Life.

Authors:  Rochit Singhal; Nilofar G Diwan; Pragya A Nair
Journal:  Indian Dermatol Online J       Date:  2018 Sep-Oct
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.